XPO1-dependent nuclear export is a druggable vulnerability in KRAS-mutant lung cancer

The common participation of oncogenic KRAS proteins in many of the most lethal human cancers, together with the ease of detecting somatic KRAS mutant alleles in patient samples, has spurred persistent and intensive efforts to develop drugs that inhibit KRAS activity(1). However, advances have been h...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Nature
Egile Nagusiak: Kim, Jimi, McMillan, Elizabeth, Kim, Hyun Seok, Venkateswaran, Niranjan, Makkar, Gurbani, Rodriguez-Canales, Jaime, Villalobos, Pamela, Neggers, Jasper Edgar, Mendiratta, Saurabh, Wei, Shuguang, Landesman, Yosef, Senapedis, William, Baloglu, Erkan, Chow, Chi-Wan B., Frink, Robin E., Gao, Boning, Roth, Michael, Minna, John D., Daelemans, Dirk, Wistuba, Ignacio I., Posner, Bruce A., Scaglioni, PierPaolo, White, Michael A.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2016
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5161658/
https://ncbi.nlm.nih.gov/pubmed/27680702
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/nature19771
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak